In Development
HXN-1001
A half-life extended anti-TL1A monoclonal antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease, formulated at high protein concentration for subcutaneous injection.
Earendil LabsProtein AI platform (OmegaFold / antibody design)
Active
Earendil's foundational protein-AI stack for antibody sequence design, structure and epitope prediction, biophysical-property scoring and closed-loop optimization, paired with high-throughput wet-lab validation. The public scientific ancestor is OmegaFold, Helixon's 2022 single-sequence structure predictor.
Latest update Sep 18, 2026
01
Current status
In production use across the internal pipeline and the Sanofi discovery collaboration. Company says the engine has produced more than 40 programs. In March 2026 Peng said the firm had integrated NVIDIA context parallelism to handle complexes up to 24,000 tokens; that claim is from a LinkedIn post, not a peer-reviewed methods paper.
02
Specifications2
03
More from Earendil Labs4
In DevelopmentHXN-1002 and HXN-1003 (Sanofi)
Two bispecific antibodies licensed exclusively to Sanofi for autoimmune and inflammatory bowel disease. HXN-1002 targets α4β7 and TL1A for moderate-to-severe ulcerative colitis and Crohn's disease. HXN-1003 targets TL1A and IL-23 and has shown synergistic activity in preclinical colitis and skin-inflammation models.
In DevelopmentHXN-1011
A recombinant humanized biparatopic antibody against two epitopes on TSLP that is designed to block both units of the heterodimeric TSLP receptor (TSLPR/CRLF2 and IL-7Rα). High-concentration subcutaneous formulation. Aimed at asthma, COPD and other TSLP-driven inflammatory diseases.
In DevelopmentOncology ADC and T-cell engager pipeline
A preclinical oncology set listed on Earendil's pipeline page: CDH17 dual-payload ADC (HXN-2001), CEACAM5/CDH17 TCE and ADC, GUCY2C TCE, DLL3 TCE and dual-payload ADC, B7-H3 ADC, TROP2/PD-L1 and EGFR/PD-L1 bispecific ADCs, and a PD-1/IL-15 fusion protein. February 2026 WuXiTecan-2 license is meant to supply payload-linkers for a subset of these ADCs.
04
More in Biotech
In DevelopmentAurora Powerhouse
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
In DevelopmentFuel Recycling
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
In DevelopmentNatrium
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.
In DevelopmentMolten Salt Energy Storage
TerraPower
Integrated thermal energy storage system using molten salt to decouple reactor output from grid delivery, enabling peak power output.